NC-PERCONA
12.1.2022 11:02:06 CET | Business Wire | Press release
Percona , a leader in open source database software and services, today announced that MultiPay Group, a global payments technology company, has signed with Percona to provide Managed Services for its MySQL open source database deployments.
MultiPay provides a unique, innovative API that acts as a single point of integration between any payment method and any acquirer. MultiPay currently serves a large number of customers in 24 countries including Zara and Frasers Group. The company enables large-scale merchants across retail, hospitality, travel and transportation sectors to accept any payment, anywhere, enabling greater freedom and flexibility for consumers and merchants alike.
However, the company’s service relies on a solid, dependable and available database infrastructure to operate efficiently. MultiPay works with Percona to get the best available advice, expertise and support for its database deployments. MultiPay relies on Percona XtraDB Cluster and Percona Monitoring and Management for its operational database and management.
Delia Pedersoli, Chief Operating Officer at MultiPay said: “Assigning our database management to Percona will enable us to realise greater efficiencies as we continue to grow our technology offering and better serve consumers and merchants with fast, seamless payment experiences. We support global retail customers with their critical payment infrastructure and we plan ahead so that we can always deliver what our customers need. Percona offers that round the clock expert support to help us ensure our databases are running at peak performance, and we can rely on Percona’s unbiased approach as we consider any future deployments too.”
Martin James, Vice President EMEA at Percona said: “The eCommerce marketplace is competitive and customers aren’t willing to put up with poor performance. MultiPay has built a unique offering that revolutionises the payment experience for consumers, and their service must keep up with what they’ve promised. Alongside running Percona XtraDB Cluster for availability, Percona provides 24/7/365 expertise and support to ensure MultiPay’s database performance is aligned with their business goals.”
As part of the agreement, Percona will help provide MultiPay with Managed Services to ensure the necessary high availability of their payment platform as well as the assistance to help them develop their long-term database and cloud strategy. The deal will result in greater cost efficiencies and easier database management for MultiPay, allowing the company to continue its global expansion and support more customers over time. MultiPay’s decision to use Percona Managed Services helps the company take care of its complex technical needs and deliver their mission critical, customer-facing services.
Links
- Percona XtraDB Cluster - https://www.percona.com/software/mysql-database/percona-xtradb-cluster
- Percona Managed Services - https://www.percona.com/services/managed-services/percona-managed-database-services
- Multipay - http://www.multipayglobalsolutions.com
Company Information
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximise application performance while streamlining database efficiencies. For more information, visit www.percona.com .
About MultiPay
Headquartered in London, Milan and now Denmark, MultiPay Global Solutions is a payments technology company that enables large merchants across the world to accept any payment, anywhere. Its all-in-one agnostic payment solution combines a unique API that acts as a single point of integration between any payment method and any acquirer. MultiPay’s gateway works across all payment channels in any sector including retail, hospitality, travel, and transportation. Combined with its personalised, couture experience, MultiPay is the single point of contact for all payment requirements and ensures it delivers payment technology and integration that is built around its customers’ bespoke requirements. For more information about MultiPay Global Solutions, visit www.multipayglobalsolutions.com
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom